Tags : alirocumab

Sanofi and Regeneron Finalizes the Restructuring of Their Collaboration on

Shots: Sanofi has finalized the planned Praluent (alirocumab) restructuring with Regeneron. The new agreement is effective from Apr 01, 2020 that simplify the Ab collaboration b/w the companies, increases efficiency and streamlines operations for Praluent Sanofi will be solely responsible for Praluent outside the US while Regeneron will be responsible for Praluent in the US. […]Read More

Sanofi and Regeneron to Restructure its Collaboration for Kevzara (sarilumab)

Shots: Sanofi and Regeneron will simplify their Ab collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement Under the proposed restructuring, Sanofi is expected to get WW rights for Kevzara and (Ex-US) rights for Praluent while Regeneron is expected to get US rights for Praluent. The companies will be responsible to fund development […]Read More